Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone.

Zold E, Nagy A, Devenyi K, Zeher M, Barta Z.

World J Gastroenterol. 2009 May 14;15(18):2293-5.

2.

Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease.

Ferkolj I, Hocevar A, Golouh R, Dolenc Voljc M.

Acta Dermatovenerol Alp Pannonica Adriat. 2006 Dec;15(4):173-7.

3.

Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease.

Alkhouri N, Hupertz V, Mahajan L.

Inflamm Bowel Dis. 2009 Jun;15(6):803-6. doi: 10.1002/ibd.20748. No abstract available.

PMID:
18942748
4.

The effect of infliximab on extraintestinal manifestations of Crohn's disease.

Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O.

Rheumatol Int. 2005 Aug;25(6):406-10. Epub 2004 Aug 12.

PMID:
15309501
5.
6.

Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.

Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, Soto-Escribano P, Calvo-Moya M, Ginard-Vicens D, Chaparro-Sánchez M, Hernández-Durán M, Castro-Senosiain B, Fernández-Villaverde A, García-Sánchez V, Domínguez-Muñoz E, Caunedo-Álvarez A, Herrerías-Gutiérrez JM.

Dig Dis Sci. 2013 Oct;58(10):2949-54. doi: 10.1007/s10620-013-2762-2. Epub 2013 Jul 5.

PMID:
23828140
7.

Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.

Ampuero J, Rojas-Feria M, Castro-Fernández M, Cano C, Romero-Gómez M.

J Gastroenterol Hepatol. 2014 Feb;29(2):291-5. doi: 10.1111/jgh.12352.

PMID:
23927379
8.

Massive pyoderma gangrenosum in a 77 year old female with Crohn's disease responsive to adalimumab.

Lipka S, Katz S, Ginzburg L.

J Crohns Colitis. 2013 Jun;7(5):427-8. doi: 10.1016/j.crohns.2012.07.029. Epub 2012 Aug 25. No abstract available.

PMID:
22926276
9.

[Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].

Rozpondek P, Zwolińska-Wcisło M, Przybylska M, Mach T.

Przegl Lek. 2011;68(9):602-5. Polish.

PMID:
22335009
10.

Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions.

Sagami S, Ueno Y, Tanaka S, Nagai K, Hayashi R, Chayama K.

Intern Med. 2015;54(17):2167-72. doi: 10.2169/internalmedicine.54.4853. Epub 2015 Sep 1.

11.

Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease.

Hadziselimovic F.

J Pediatr Gastroenterol Nutr. 2008 Feb;46(2):208-11. doi: 10.1097/MPG.0b013e318124504b. No abstract available.

PMID:
18223382
12.

Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.

Kouklakis G, Moschos J, Leontiadis GI, Kadis S, Mpoumponaris A, Molyvas E, Minopoulos GI.

Rom J Gastroenterol. 2005 Dec;14(4):401-3.

13.

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.

Barreiro-de-Acosta M, Lorenzo A, Domínguez-Muñoz JE.

Rev Esp Enferm Dig. 2012 Sep;104(9):468-72.

14.

A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab.

Quin A, Kane S, Ulitsky O.

Nat Clin Pract Gastroenterol Hepatol. 2008 May;5(5):278-81. doi: 10.1038/ncpgasthep1099. Epub 2008 Mar 25.

PMID:
18364718
15.

Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.

Cordero Ruiz P, Castro Márquez C, Méndez Rufián V, Castro Laria L, Caunedo Álvarez A, Romero Vázquez J, Herrerías Gutiérrez JM.

Rev Esp Enferm Dig. 2011 Jun;103(6):294-8.

16.

Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation: a case report.

Molnar T, Farkas K, Nagy F, Wittmann T.

Inflamm Bowel Dis. 2008 Dec;14(12):1752-3. doi: 10.1002/ibd.20485. No abstract available.

PMID:
18452207
17.

Use of infliximab in pyoderma gangrenosum.

Hewitt D, Tait C.

Australas J Dermatol. 2007 May;48(2):95-8.

PMID:
17535196
18.

[Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study].

López Palacios N, Mendoza JL, Taxonera C, Lana R, Fuentes Ferrer M, Díaz-Rubio M.

Rev Esp Enferm Dig. 2008 Nov;100(11):676-81. Spanish.

19.

Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.

Zaccagna A, Bertone A, Puiatti P, Picciotto F, Sprujevnik T, Santucci R, Rossini FP.

Eur J Dermatol. 2003 May-Jun;13(3):258-60.

PMID:
12804985
20.

Adalimumab as therapy for fistulizing orofacial Crohn's disease.

Doherty G, Kalachand R, Patchett S.

Inflamm Bowel Dis. 2010 Feb;16(2):184-5. doi: 10.1002/ibd.20958. No abstract available.

PMID:
19408321

Supplemental Content

Support Center